Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Suven Pharmaceuticals Ltd. ( (IN:SUVENPHAR) ) has issued an announcement.
Suven Pharmaceuticals Ltd. has received a cautionary email from the National Stock Exchange of India Limited (NSE) regarding a delay in notifying the stock exchanges about the appointment of its Statutory Auditors, which occurred on July 12, 2024. Despite the delay, the company assures that there is no impact on its financial, operational, or other activities, and it commits to adhering to the disclosure requirements under SEBI Listing Regulations in the future.
More about Suven Pharmaceuticals Ltd.
Suven Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development and manufacturing of active pharmaceutical ingredients and intermediates. The company is based in India, with its registered office in Mumbai and corporate office in Hyderabad.
YTD Price Performance: 3.19%
Average Trading Volume: 12,966
Current Market Cap: 295.2B INR
Learn more about SUVENPHAR stock on TipRanks’ Stock Analysis page.